Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)

US7981420B2 · kind B2 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Bernhard Mueller · Neustadt, DE
• Philippe Monnier · Meylan, FR
• Paolo Macchi · Tübingen, DE
• Friedrich Bonhoeffer · Tübingen, DE
• Bernd Stahl · Tübingen, DE
• Matthias Mann · Odense, DK
• Jens S. Anderson · Odense, DK

Key dates

• Filing date: Dec 21, 2001
• Grant date: Jul 19, 2011
• Expiry date: Apr 9, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system. Furthermore, the invention provides for the use of a modulator of a polypeptide having or comprising said amino acid sequence of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with angiogenic disorders or disorders of the cardio-vascular system. In addition the invention provides for the use of said polypeptide or said functional fragment or derivative thereof for the…